trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Elderly patients tolerate chemotherapy poorly.

the verdict
CONTESTED
contested - the weight sits with the supporting side
Recorded sources
3 sources for · 2 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that elderly patients tolerate chemotherapy poorly?

Partly. While elderly patients face higher risks of chemotherapy toxicity due to age-related physiological decline and frailty, current evidence emphasizes that chronological age alone is an imperfect predictor, and carefully selected older patients can tolerate treatments well when managed with geriatric assessments.

Verdict: CONTESTED · 3 sources for, 2 against · Last checked

The analysis

The claim that elderly patients tolerate chemotherapy poorly is a recognized clinical concern, often driven by physiological vulnerability, multimorbidity, and frailty (supported by papers 0, 2, and 4). However, modern geriatric oncology increasingly emphasizes that chronological age is less predictive of toxicity and poor outcomes than functional status and comorbidity burden, and carefully selected older adults can safely tolerate cancer therapies (contested by papers 8 and 11). Thus, the balance of evidence is contested, moving away from a blanket assumption of poor tolerance toward frailty-adapted evaluations.

The evidence we hold leans leans supported

How this was weighed

official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x

  • Predicting Chemotherapy-Related Adverse Events in Elderly Ca · peer-reviewed · supports · weight 1.05 · 2022
  • Effectiveness of a Geriatric Assessment-Driven Intervention · peer-reviewed · supports · weight 1 · 2026
  • Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Co · peer-reviewed · supports · weight 1 · 2026
  • Association of Chronological Age and Comorbidity Burden with · peer-reviewed · refutes · weight 1 · 2026
  • Safety and efficacy of PRaG therapy in elderly cancer patien · peer-reviewed · refutes · weight 1 · 2026
Evidence for · 3
2022
Get citation
Suto, H., Inui, Y., & Okamura, A. (2022). Predicting Chemotherapy-Related Adverse Events in Elderly Cancer Patients with Prior Anticancer Therapy. doi.org. https://doi.org/10.3390/curroncol29040177

Evidence against · 2
2026
Get citation
H, S., M, M., T, I., T, S., H, N., M, H., T, S., M, G., T, S., T, F., K, B., M, N., K, N., & H, S. (2026). Association of Chronological Age and Comorbidity Burden with Outcomes After Proton Beam Therapy for Hepatocellular Carcinoma.. doi.org. https://doi.org/10.3390/cancers18183005

See more details
More for · 2
2026
Get citation
S, S., G, J., S, D., S, K., S, Z. A., & HS, G. (2026). Effectiveness of a Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy Toxicities in Elderly Cancer Patients.. doi.org. https://doi.org/10.7759/cureus.114399

2026
Get citation
V, K., L, N., C, F., V, K., K, T., & K, T. (2026). Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions.. doi.org. https://doi.org/10.3390/jcm15176592

More against · 1
2026
Get citation
X, Z., M, Y., J, Z., Y, K., M, X., R, C., Q, Y., P, X., & L, Z. (2026). Safety and efficacy of PRaG therapy in elderly cancer patients.. doi.org. https://doi.org/10.1093/immadv/ltag019

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work